Concepedia

Publication | Open Access

A computational combinatorial approach identifies a protein inhibitor of superoxide dismutase 1 misfolding, aggregation, and cytotoxicity

16

Citations

66

References

2017

Year

Abstract

Molecular agents that specifically bind and neutralize misfolded and toxic superoxide dismutase 1 (SOD1) mutant proteins may find application in attenuating the disease progression of familial amyotrophic lateral sclerosis. However, high structural similarities between the wild-type and mutant SOD1 proteins limit the utility of this approach. Here we addressed this challenge by converting a promiscuous natural human IgG-binding domain, the hyperthermophilic variant of protein G (HTB1), into a highly specific aggregation inhibitor (designated HTB1<sub>M</sub>) of two familial amyotrophic lateral sclerosis-linked SOD1 mutants, SOD1<sup>G93A</sup> and SOD1<sup>G85R</sup> We utilized a computational algorithm for mapping protein surfaces predisposed to HTB1 intermolecular interactions to construct a focused HTB1 library, complemented with an experimental platform based on yeast surface display for affinity and specificity screening. HTB1<sub>M</sub> displayed high binding specificity toward SOD1 mutants, inhibited their amyloid aggregation <i>in vitro</i>, prevented the accumulation of misfolded proteins in living cells, and reduced the cytotoxicity of SOD1<sup>G93A</sup> expressed in motor neuron-like cells. Competition assays and molecular docking simulations suggested that HTB1<sub>M</sub> binds to SOD1 via both its α-helical and β-sheet domains at the native dimer interface that becomes exposed upon mutated SOD1 misfolding and monomerization. Our results demonstrate the utility of computational mapping of the protein-protein interaction potential for designing focused protein libraries to be used in directed evolution. They also provide new insight into the mechanism of conversion of broad-spectrum immunoglobulin-binding proteins, such as HTB1, into target-specific proteins, thereby paving the way for the development of new selective drugs targeting the amyloidogenic proteins implicated in a variety of human diseases.

References

YearCitations

Page 1